|
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Profit Warning Essen, Germany, July 10, 2023 – Evonik Industries AG is already today publishing the following preliminary figures for the second quarter of 2023 and adjusting its outlook for the financial year 2023. Based on preliminary, non-audited figures, Evonik expects an adjusted EBITDA* of € 430 million to € 450 million in the second quarter of 2023 (2022: € 728 million). The current market expectation is € 448 million (Vara Research analyst consensus as of July 10, 2023). The main reason for this development is the lack of economic recovery to date. In addition, very weak demand across all end markets and sustained reduction in inventories by customers continued in the second quarter. Overall, volumes sold remained at the very low level of the previous quarter. In the specialty chemicals businesses in particular, Evonik nevertheless managed to keep sales prices stable for the most part. In the second quarter, however, all chemical divisions achieved noticeably lower earnings than in the strong prior-year period. The economic development was also reflected in Group sales. According to preliminary figures, Evonik's sales in the second quarter of 2023 were just under € 4 billion. According to consensus, sales of € 4,081 million are expected. For the full year 2023, Evonik had previously expected an adjusted EBITDA* in the range of € 2.1 billion to € 2.4 billion, although the company had recently only targeted the lower end. Evonik now expects demand to remain weak without any economic recovery throughout the second half of the year. Against this backdrop, Evonik is adjusting its outlook for the full year 2023 as follows: Evonik now expects an adjusted EBITDA* of between € 1.6 billion and € 1.8 billion (previously: € 2.1 - € 2.4 billion). The cost-cutting measures already introduced in the second half of 2022, which already had a supporting effect on earnings in the first half of 2023, will continue to ramp up in the second half of 2023 and contribute around € 250 million for the full year 2023. The sales outlook is adjusted to a range between € 14 billion and € 16 billion (previously: € 17 billion - € 19 billion). Accordingly, Evonik expects the cash conversion rate to continue to develop towards a target value of 40 % (2022: 32 %), but - contrary to previously expected - an absolutely higher free cash flow than in the previous year (2022: € 785 million) will not be achievable with the lower operating result. Evonik Industries AG intends to publish the final figures for the second quarter of 2023 as planned on August 10, 2023.
Further information will be published today by Evonik Industries AG in a press release.
*Explanations of the key performance indicators used can be found in the Financial Report 2022 of Evonik Industries AG starting on page 226.
The Financial Report 2022 is available at: https://files.evonik.com/shared-files/financial-report-2022-8613.pdf
Contact/Person making the notification: Tim Lange Leiter Investor Relations +49 201 177-3150 tim.lange@evonik.com
End of Inside Information
10-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | investor-relations@evonik.com |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013 |
| WKN: | EVNK01 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 1676429 |
| End of Announcement | EQS News Service |
|
|
1676429 10-Jul-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
